Targeting regulatory T cells in the treatment of type 1 diabetes mellitus

S. M. Cabrera, M. R. Rigby, Raghu Mirmira

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.

Original languageEnglish
Pages (from-to)1261-1272
Number of pages12
JournalCurrent Molecular Medicine
Volume12
Issue number10
DOIs
StatePublished - 2012

Fingerprint

T-cells
Regulatory T-Lymphocytes
Medical problems
Type 1 Diabetes Mellitus
Eragrostis
Peripheral Tolerance
T-Lymphocytes
Homeostasis
Therapeutics
Investigational Therapies
Islets of Langerhans
Autoimmune Diseases
Cell Count
Health
Glucose

Keywords

  • Autoimmunity
  • Effector t cells
  • Regulatory t cells
  • Teffs
  • Tregs
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. / Cabrera, S. M.; Rigby, M. R.; Mirmira, Raghu.

In: Current Molecular Medicine, Vol. 12, No. 10, 2012, p. 1261-1272.

Research output: Contribution to journalArticle

Cabrera, S. M. ; Rigby, M. R. ; Mirmira, Raghu. / Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. In: Current Molecular Medicine. 2012 ; Vol. 12, No. 10. pp. 1261-1272.
@article{5f990a7e22dc4122aa8afa57012bd0cf,
title = "Targeting regulatory T cells in the treatment of type 1 diabetes mellitus",
abstract = "Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.",
keywords = "Autoimmunity, Effector t cells, Regulatory t cells, Teffs, Tregs, Type 1 diabetes mellitus",
author = "Cabrera, {S. M.} and Rigby, {M. R.} and Raghu Mirmira",
year = "2012",
doi = "10.2174/156652412803833634",
language = "English",
volume = "12",
pages = "1261--1272",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Targeting regulatory T cells in the treatment of type 1 diabetes mellitus

AU - Cabrera, S. M.

AU - Rigby, M. R.

AU - Mirmira, Raghu

PY - 2012

Y1 - 2012

N2 - Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.

AB - Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.

KW - Autoimmunity

KW - Effector t cells

KW - Regulatory t cells

KW - Teffs

KW - Tregs

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84870225003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870225003&partnerID=8YFLogxK

U2 - 10.2174/156652412803833634

DO - 10.2174/156652412803833634

M3 - Article

C2 - 22709273

AN - SCOPUS:84870225003

VL - 12

SP - 1261

EP - 1272

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 10

ER -